Leflunomid

Leflunomide, the active ingredient in Leflunomid, is an immunomodulatory agent (pyrimidine synthesis inhibitor) presented as an oral formulation for oral use. It is employed to manage inflammatory joint diseases such as rheumatoid arthritis, psoriatic arthritis and juvenile idiopathic arthritis in adult and pediatric patients.

GNH USA supplies Leflunomid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to multiple regions. Customers benefit from reliable delivery timelines and dedicated technical support.

Leflunomide is indicated for several autoimmune joint disorders where it modifies disease activity.

Rheumatoid arthritis: reduces joint inflammation, pain and structural damage, improving functional ability. Psoriatic arthritis: alleviates skin and joint symptoms, slowing disease progression. Juvenile idiopathic arthritis: controls systemic inflammation and joint involvement in pediatric patients.

Leflunomide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Diarrhea: loose stools or increased frequency. - Nausea: feeling of sickness or urge to vomit. - Elevated liver enzymes: increased ALT/AST levels detected in blood tests. - Hair loss: thinning or shedding of scalp hair.

Serious or Rare Side Effects: - Severe liver injury: jaundice, hepatitis or liver failure requiring monitoring. - Aplastic anemia: pancytopenia with fatigue, infections and bleeding risk. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe cutaneous reactions. - Pulmonary toxicity: interstitial lung disease presenting with cough and dyspnea.

When prescribing leflunide, clinicians should observe several safety precautions to minimize risk. - Pregnancy: contraindicated; teratogenic risk requires effective contraception for women of childbearing potential. - Liver function: baseline and periodic monitoring of transaminases is essential. - Hematology: complete blood count should be checked regularly for signs of cytopenia. - Infection risk: assess for active infections before initiation and monitor during therapy. - Drug interactions: avoid concomitant use with potent CYP1A2 inhibitors or warfarin without dose adjustment. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and direct sunlight.

Leflunomide can affect the pharmacokinetics of several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent use with strong CYP1A2 inhibitors (e.g., fluvoxamine) markedly increases teriflunomide levels and risk of toxicity. - Co‑administration with warfarin may enhance anticoagulant effect, leading to bleeding.

Moderate Interactions (Monitor Closely): - Combined therapy with methotrexate may increase hepatic toxicity; liver enzymes should be closely monitored. - Use with azathioprine can augment bone marrow suppression; regular blood counts are advised. - Statins may have increased risk of myopathy; monitor muscle symptoms and CK levels.